Patent · US Active

Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa

US9822185B2 · kind B2 · utility

0Cited by

10References

4Claims

0Family size

Assignee

STALLERGENES · FR

Inventors

Thierry Batard · Versailles, FR
Philippe Moingeon · Verrières-le-Buisson, FR
Laurent Mascarell · Paris, FR
Aline Zimmer · Groß-Gerau, DE
Emmanuel Nony · Antony, FR

Key dates

Filing date	Oct 9, 2015
Grant date	Nov 21, 2017
Priority date	—
Expiry date	Oct 9, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.